Description: Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, a HIF-PH inhibitor, which is in Phase IIb clinical trials for patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company is also developing a development program for patients dependent on dialysis. Akebia Therapeutics, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Home Page: www.akebia.com
AKBA Technical Analysis
245 First Street
Cambridge,
MA
02142
United States
Phone:
617 871 2098
Officers
| Name | Title |
|---|---|
| Mr. John P. Butler MBA | CEO, Pres & Director |
| Mr. David A. Spellman | Sr. VP, CFO & Treasurer |
| Mr. Michel Dahan | Sr. VP & COO |
| Dr. Steven Keith Burke | Sr. VP of R&D and Chief Medical Officer |
| Ms. Violetta Cotreau | Sr. VP, Chief Accounting Officer & Principal Accounting Officer |
| Ms. Nicole R. Hadas | Sr. VP, Chief Legal Officer & Sec. |
| Mercedes Carrasco | Director of Corp. Communications |
| Mr. Douglas Jermasek M.B.A. | VP of Marketing & Strategy |
| Ms. Meredith Bowman | Sr. VP of People |
| Dr. Thierry Bilbault Ph.D. | Sr. VP of Manufacturing & Pharmaceutical Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.1167 |
| Price-to-Sales TTM: | 0.2809 |
| IPO Date: | 2014-03-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 426 |